Earnings

Kymera Therapeutics Q3 EPS $(1.32) Misses $(1.27) Estimate

Oct 29, 2026 · 07:05 AM ET· updated 50m ago

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.27) by 3.94 percent. This is a 40.43 percent decrease over losses of $(0.94) per share

Why It Matters

Kymera lost more money than experts thought it would this quarter. Watch if the company can slow down its spending before it runs out of cash.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

KYMR121.88

+4.31 (+3.66%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.